Utility of CEA and CA 19-9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix

Journal of Surgical Oncology

Volumn 87, Issue 4, 2004, Pages 162-166

  Carmignani, C Pablo ^a   Hampton, Regina ^b   Sugarbaker, Christina E ^a   Chang, David ^c   Sugarbaker, Paul H ^a  

^a WASHINGTON CANCER INSTITUTE   (United States)

^b HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c WESTAT   (United States)

Author keywords

Appendiceal cancer; CA 19 9; Carcinembryonic antigen; Carcinomatosis; CEA; Cytoreductive surgery; Pseudomyxoma peritonei

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

APPENDIX CANCER; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CORRELATION ANALYSIS; CYTOREDUCTIVE SURGERY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; HUMAN; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; PERITONEUM METASTASIS; PERITONEUM PSEUDOMYXOMA; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; REOPERATION;

ADENOCARCINOMA, MUCINOUS; APPENDICEAL NEOPLASMS; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; HUMANS; PERITONEAL NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; PSEUDOMYXOMA PERITONEI; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 4444376038     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20107     Document Type: Article

References (15)

1. Bast RC, Jr., Ravdin P, Hayes DF, et al.: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-1878.
2. Meier W, Baumgartner L, Stieber P, et al.: CA125 based diagnosis and therapy in recurrent ovarian cancer. Anticancer Res 1997;17:3019-3020.
3. Gels ME, Hoekstra HJ, Sleijfer DT, et al.: Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: A single-center 10-year experience. J Clin Oncol 1995;13:1188-1194.
4. Roberts SG, Blute ML, Bergstralh EJ, et al.: PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001;76:576-581.
5. Sugarbaker PH, Zamcheck N, Moore FD: Assessment of serial carcinoembryonic antigen (CEA) assays in postoperative detection of recurrent colorectal cancer. Cancer 1976;38:2310-2315.
6. Goslin R, Steele G, Jr., Macintyre J, et al.: The use of preoperative plasma CEA levels for the stratification of patients after curative resection of colorectal cancers. Ann Surg 1980;192:747-751.
7. Northover J, Houghton J, Lennon T: CEA to detect recurrence of colon cancer. Jama 1994;272:31.
8. c8. Esquivel J, Sugarbaker PH: Clinical presentation of the Pseudomyxoma peritonei syndrome. Br J Surg 2000;87:1414-1418.
9. Esquivel J, Sugarbaker PH: Second-look surgery in patients with peritoneal dissemination from appendiceal malignancy: Analysis of prognostic factors in 98 patients. Ann Surg 2001;234:198-205.
10. Sugarbaker PH, Ronnett BM, Archer A, et al.: Pseudomyxoma peritonei syndrome. Adv Surg 1996;30:233-280.
11. Sugarbaker PH, Jablonski KA: Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995;221:124-132.
12. Ronnett BM, Shmookler BM, Sugarbaker PH, et al.: Pseudomyxoma peritonei: New concepts in diagnosis, origin, nomenclature, and relationship to mucinous borderline (low malignant potential) tumors of the ovary. Anat Pathol 1997;2:197-226.
13. Glehen O, Mohamed F, Sugarbaker P: Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg (in press).
14. Jacquet P, Jelinek JS, Chang D, et al.: Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive surgery. J Am Coll Surg 1995;181:530-538.
15. Moertel CG, O'Fallon JR, Go VL, et al.: The preoperative carcino-embryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer 1986;58:603-610.